Abstract 1117P
Background
Skin melanoma, particularly acral melanoma, is known for its poor prognosis, often exacerbated by infections and chronic ulcers. Recent research has highlighted the significant role of intratumoral microbiota in various cancers, but its impact remains less understood in Chinese patients with skin melanoma. This study aims to investigate the intratumoral microbiota in melanoma among this group and explore its potential influence on disease progression.
Methods
One hundred melanoma tissue samples from stage III/IV skin or acral melanoma patients at Sun Yat-sen University Cancer Center, collected between 2015 and 2021, were retrospectively collected and underwent LPS immunohistochemistry (IHC). Kaplan-Meier analysis was used to assess the relation of LPS expression and patients overall survival. Microbial diversity was analyzed through 16S rRNA sequencing. Spatial transcriptomics was applied to map LPS-positive and LPS-negative regions, enabling the exploration of transcriptional differences and cell distributions.
Results
Patients with high LPS levels exhibited a median overall survival (mOS) of 13.7 months (95% CI, 10.6–16.9), which was shorter compared to those with low LPS levels, who had not yet reached median survival. Analysis of tumor microbiota revealed significant diversity, with high proportions of Bifidobacterium, Vibrio, Bacillus, Clostridium sensu stricto, and Pseudomonas, among which Pseudomonas was the dominant genus. Spatial transcriptomic analysis of LPS-positive melanoma tissues showed an increased proportion of M2 macrophages and a decreased proportion of effector T cells. Gene set enrichment analysis (GSEA) further indicated the activation of epithelial-mesenchymal transition (EMT) pathways.
Conclusions
High levels of microbiota within melanoma tissues are correlated with poor overall survival and may facilitate tumor immune evasion and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1132P - Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case series
Presenter: Iris Dirven
Session: Poster session 04
1133P - Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry
Presenter: Juergen Becker
Session: Poster session 04
1134P - Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
Presenter: Celeste Lebbe
Session: Poster session 04
1135P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma
Presenter: Maximilian Haist
Session: Poster session 04
1136P - Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
Presenter: Eva Muñoz-Couselo
Session: Poster session 04
1137P - Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
Presenter: Justine Cohen
Session: Poster session 04
1138P - A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters
Presenter: Rikke Holmstroem
Session: Poster session 04
1139TiP - IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Presenter: Marcus Butler
Session: Poster session 04
1140TiP - Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Presenter: Joséphine Janssen
Session: Poster session 04
1210P - Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
Presenter: Marina Garassino
Session: Poster session 04